The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Dechert LLP

1095 AVENUE OF THE AMERICAS, NEW YORK, NY 10036-6797, USA
Tel:
Work +1 212 698 3500
Fax:
Fax +1 212 698 3599
Email:
Web:
www.dechert.com

Andrew J Levander

Tel:
Work +1 212 698 3683
Email:
Dechert LLP

Work Department

Litigation

Career

Andrew J. Levander is Chair of the firm’s Policy Committee and a partner in the white collar and securities litigation group. A former Assistant U.S. Attorney for the Southern District of New York in the Securities and Commodities Fraud Unit, Mr. Levander is consistently recognized for excellence in the practice of law. Mr. Levander is a Fellow in the American College of Trial Lawyers, which is widely considered to be the premier professional trial organization in the United States. Since 2004, he has been cited as a leading lawyer by Chambers USA, a referral guide to leading lawyers in the United States based on the opinions of their peers and clients. In 2018, Mr. Levander was named as a Litigator of the Year by The American Lawyer for being a lawyer who has, “reshaped the law, the industries in which their clients operate and the way their colleagues in the bar approach cases.” Mr. Levander received the Chambers USA Award for Excellence in White Collar Crime & Government Investigations in both 2013 and 2010. He has also been honored by Law360The Best Lawyers in America, and Benchmark Litigation for his litigation skills.

Member

Fellow, American College of Trial Lawyers

Education

Tufts University, B.A., 1973, summa cum laude; Columbia Law School, J.D., 1977, Kent Scholar, Notes and Comments Editor of the Columbia Law Review


United States: Dispute resolution

Corporate investigations and white-collar criminal defense

Within: Leading individuals: Corporate investigations and white-collar criminal defense: advice to individuals

Andrew Levander - Dechert LLP

Within: Corporate investigations and white-collar criminal defense

The group at Dechert LLP, which is chaired by Chicago-based David Kistenbroker and New York-based David Kelley, specializes in securities matters, as well as corporate governance and FCPA issues, congressional and internal investigations, US export controls and economic sanctions. Andrew Levander and Benjamin Rosenberg in New York are defending the director of a Hong Kong-based NGO, Dr Chi Ping Patrick Ho, in a criminal prosecution for alleged violations of the FCPA and money laundering charges relating to the bribery of Chadian and Senegalese government officials for the benefit of a Chinese energy company. Alongside Neil Steiner, Levander and a number of associated entities in multiple government agency investigations concerning the purchase of two not-for-profit nursing homes, which were promptly closed and sold to a luxury real estate developer, allegedly removing a deed restriction on the property; ultimately the client was cleared of any wrongdoing. Cathy Botticelli, Vincent Cohen are the names to note in Washington DC, and New York-based Jonathan Streeter is also recommended. In Philadelphia, the bench was greatly strengthened by the arrival of Michael McGinley, who joined the firm in April 2018 after serving as special assistant and associate counsel to President Trump.

[back to top]

Securities litigation - defense

Within: Securities litigation - defense

Dechert LLP has securities litigators in offices across the US and frequently handles class actions, shareholder derivative suits, mutual fund litigation, broker-dealer disputes and regulatory enforcement proceedings. The 'very likable' David Kistenbroker, who practices in both New York and Chicago, is global co-chair of the trial, investigations and securities group. He acted for Anavex Life Sciences Corporation and its officers in a 10b5 case that alleged false and misleading statements were made about the efficacy of the company’s experimental Alzheimer’s drug; Joni Jacobsen in Chicago also played a key role in that case. The same team also acted for Antares Pharma Inc in several cases, including a suit alleging that the company provided insufficient information to the FDA in support of Xyosted and overstated its approval prospects. In New York, firm chairman Andrew Levander, who handled a 33 Act claim for CHC Group, and global litigation head Matthew Larrabee are recommended, as is Michael Kichline in Philadelphia.

[back to top]


Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to